NKTX Overview

Nkarta, Inc. is a clinical-stage biopharmaceutical company advancing the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen for the treatment of patients with autoimmune diseases and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. NKX019 is engineered with a humanized CD19-directed CAR for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B cells as well as those implicated in autoimmune disease and B cell-derived malignancies. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies.

Wall Street analysts forecast NKTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NKTX is12.33 USD with a low forecast of 10.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Nkarta Inc revenue for the last quarter amounts to 0.00 USD, decreased

Nkarta Inc. EPS for the last quarter amounts to -0.37 USD, decreased -13.95

Nkarta Inc (NKTX) has 108 emplpoyees as of May 29 2026.

Today NKTX has the market capitalization of 228.23M USD.